source
- Astellas marks a decade of CLDN18.2 research, eyeing patient selection and treatment sequencingAstellas highlighted a ten‑year journey that took the CLDN18.2 protein from a scientific hypothesis to a validated target in cancer research. The protein, initially noted for its presence on tumor…
- OMass Therapeutics secures $310M Series C, eyes status as Britain’s leading biotechOMass Therapeutics, an Oxford‑based biotech still in pre‑clinical stage, announced a new financing round that brings in $310 million. The series C, co‑led by Bain Capital Life Sciences, Forbion an…